Exelixis: Pinning Hopes On Cracking One Of The Toughest Nuts
Exelixis' future depends on trial outcomes and patent risks. Find out why EXEL stock is a "Sell" despite cabozantinib's ...
pharmaphorum4d
MSD hits a hurdle with its LAG-3 programme
compared to standard care with kinase inhibitor regorafenib and trifluridine and tipiracil chemotherapy. It's another setback for the LAG-3 category in MSS colorectal cancer, coming after Bristol ...
pharmaphorum1d
Blueprint pays the price of Ayvakit phase 3 miss as FDA rejects drug
The second part was for fourth-line use in GIST patients, and the agency decided it wanted to see the results of an ongoing phase 3 trial comparing Ayvakit to Bayer’s Stivarga (regorafenib ...
Medscape3d
Gender-specific Genomic Profiling in Metastatic Colorectal Cancer Patients Treated with 5-fluorouracil and Oxaliplatin
Aims: Survival and response rates in metastatic colorectal cancer remain poor, despite advances in drug development. There is increasing evidence to suggest that gender-specific differences may ...